VX-01 pill for diabetic eye disease study
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests if an oral medication called VX-01 can help people with diabetic eye disease (non-proliferative diabetic retinopathy) that is moderate to severe but not yet at the most advanced stage. It may be an option if you have type 1 or type 2 diabetes and have not had certain prior eye treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with type 1 or type 2 diabetes
- Moderate to severe non-proliferative diabetic retinopathy (NPDR) in at least one eye, confirmed by a central reading center
- Body mass index (BMI) between 18 and 40
- Good enough vision in the study eye (70 or more letters on a standard eye chart)
- No diabetic macular edema requiring treatment or central-involved macular edema
- No previous treatment with anti-VEGF injections or steroids in the eye within certain timeframes
- Women of childbearing potential must use two forms of birth control and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This trial tests if a new eye drop, NPDR-01, can help slow or improve early diabetic retinopathy (damage to the retina caused by diabetes). It is for people with type 1 or type 2 diabetes who have non-proliferative diabetic retinopathy and have not had certain eye treatments.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.